Tue, August 10, 2010
Mon, August 9, 2010
Fri, August 6, 2010
Thu, August 5, 2010
Wed, August 4, 2010
Tue, August 3, 2010
Mon, August 2, 2010
Fri, July 30, 2010
Thu, July 29, 2010
Wed, July 28, 2010
Tue, July 27, 2010
Mon, July 26, 2010
Fri, July 23, 2010
Thu, July 22, 2010
Wed, July 21, 2010
Tue, July 20, 2010
[ Tue, Jul 20th 2010 ] - Market Wire
00 AM EDT
Mon, July 19, 2010

Micromet to Report Second Quarter 2010 Financial Results on August 5


//health-fitness.news-articles.net/content/2010/ .. -quarter-2010-financial-results-on-august-5.html
Published in Health and Fitness on Thursday, July 29th 2010 at 5:11 GMT by Market Wire   Print publication without navigation


BETHESDA, Md.--([ BUSINESS WIRE ])--Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that it will host a conference call and audio webcast to review its second quarter 2010 results on Thursday, August 5, 2010, at 8:30 AM ET.

To participate in the conference call, please dial 866-730-5763 (domestic) or 857-350-1587 (international) and reference the access code 46379708. The presentation will be available via webcast at:
[ http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=197259&eventID=3196706 ]

A replay of the call will be available from 11:30 AM ET on August 5, 2010 until midnight ET on September 5, 2010. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 58638627. The archived webcast will be available for 30 days in the Investor Relations section of the Micromet website at [ www.micromet.com ].

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer Schering Pharma, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at [ www.micromet.com ].


Publication Contributing Sources